The blockade of terminal complement pathway by eculizumab [11], a monoclonal antibody (moAb) against complement component 5 (C5), abrogates intravascular hemolysis with the consequent normalization of lactate dehydrogenase (LDH) levels in almost all patients suffering from PNH. Here, C5 is linked to hemolysis.